Helixgate

Helixgate

Uncategorized

Hikma vs. Amarin generic drug case heads to Supreme Court arguments

Hikma vs. Amarin generic drug case heads to Supreme Court arguments

Published

on

When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching.

The case could have broad implications on how new generics get …​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Viridian data lift prospects for thyroid eye disease drug

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

Read More

Published

on

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

Read More

Continue Reading

Uncategorized

Pfizer is a 2029 story but Q126 lays foundation for growth

Published

on

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Continue Reading

Uncategorized

Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83M

Published

on

A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets.

🧬 Second life for a gene therapy: A Cleveland-based biotech called …

Continue Reading
Advertisement

Trending